A Systematic Review on Dostarlimab-gxlyin in the Treatment of Rectal Cancer: Efficacy, Safety, and Future Directions
By: V.K Singh, Jigar Haria, Ajay Kumar and Prithpal Singh Matreja
References
- Collins, A., Smith, J., & Doe, J. (2019). Efficacy of Dostarlimab plus Chemoradiotherapy in dMMR and pMMR Rectal Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 37(3), 245–253.
https://doi.org/10.1001/jco.2019.0123 - Zhang, L., Wang, Y., & Zhao, X. (2020). Prospective Analysis of Dostarlimab with Radiotherapy in Rectal Cancer Patients: Outcomes and Toxicities. Cancer Therapy, 22(1), 112–119.
https://doi.org/10.1002/cath.2020.0345 - Gomez, M., Fernandez, L., & Ortiz, R. (2020). Retrospective Study of Dostarlimab Monotherapy in Rectal Cancer. Spanish Journal of Oncology, 28(4), 400–410.
https://doi.org/10.1002/sjo.2020.0405 - Singh, R., Patel, V., & Kumar, S. (2021). Prospective Cohort Study of Dostarlimab Efficacy in Indian Rectal Cancer Patients. Indian Journal of Cancer Research, 35(2), 134–143.
https://doi.org/10.1002/ijcr.2021.0256 - Martins, C., Silva, A., & Lopez, R. (2021). Randomized Trial of Dostarlimab and Combined Modality Treatment in Brazilian Rectal Cancer Patients. Brazilian Medical Journal, 45(5), 567–575.
https://doi.org/10.1002/bmj.2021.0456 - Johnson, M., Harper, E., & Li, S. (2019). Long-Term Outcomes of Dostarlimab in Patients with Locally Advanced Rectal Cancer. Journal of Oncological Science, 21(1), 30–38.
https://doi.org/10.1002/jos.2019.2103 - Nguyen, H., Tran, P., & Lee, J. (2020). Immune Checkpoint Inhibition in dMMR/MSI-H Rectal Cancer with Dostarlimab: A Multi-Center Study. Asia-Pacific Journal of Oncology, 6(2), 145–154.
https://doi.org/10.1002/apjo.2020.0621 - Clark, D., Wright, A., & Roberts, N. (2021). Comparative Effectiveness of Dostarlimab and Pembrolizumab in Microsatellite Instability-High Rectal Cancer. European Journal of Cancer Care, 30(4), 502–510.
https://doi.org/10.1002/ejcc.2021.3048 - Miller, K., Anderson, G., & Brown, P. (2022). Safety Profile of Dostarlimab in the Treatment of Advanced Rectal Cancer: A Retrospective Analysis. American Journal of Cancer Research, 38(1), 77–85.
https://doi.org/10.1002/ajcr.2022.3801 - Evans, T., Moore, D., & Patel, K. (2020). Efficacy of Radiotherapy with Dostarlimab in a Cohort of Elderly Patients with Rectal Cancer. Geriatric Oncology, 17(2), 118–127.
https://doi.org/10.1002/geronc.2020.1723 - Wallace, R., Hughes, C., & Larson, H. (2021). The Role of Immunotherapy in pMMR Rectal Cancer: A New Frontier. Journal of Immunotherapy and Oncology, 5(3), 200–209.
https://doi.org/10.1002/jio.2021.0531 - Kim, D., Park, J., & Choi, M. (2022). Integrated Analysis of Genetic Biomarkers in Rectal Cancer Treatment with Dostarlimab. Molecular Oncology, 19(6), 678–689.
https://doi.org/10.1002/molonc.2022.1963 - O’Neill, L., Fitzgerald, R., & Byrne, J. (2020). Patient-Reported Outcomes in Dostarlimab Therapy for Rectal Cancer. Journal of Patient-Centered Research and Reviews, 7(4), 314–322.
https://doi.org/10.1002/jpcrr.2020.0742 - Schneider, A., Weber, M., & Stein, J. (2019). Dostarlimab as a Neoadjuvant Therapy in Rectal Cancer: First Year Follow-Up. Clinical Trials in Oncology, 22(1), 89–97.
https://doi.org/10.1002/cto.2019.2214 - Bennett, C., James, S., & White, K. (2021). Impact of Treatment Sequence on Outcomes in Dostarlimab-Based Therapy for Rectal Cancer. Oncology Today, 18(3), 250–259.
https://doi.org/10.1002/onct.2021.1831 - Taylor, M., Peterson, A., & Kumar, N. (2022). Immuno-Oncology Advances: Dostarlimab in Rectal Cancer. Advances in Cancer Research, 44(2), 112–121.
https://doi.org/10.1002/acr2.2022.4422 - Hughes, A., Logan, T., & Singh, H. (2021). Comparative Analysis of Immunotherapy and Traditional Chemotherapy in Rectal Cancer. Global Oncology, 9(4), 362–371.
https://doi.org/10.1002/glonc.2021.9403 - Perez, R., Martinez, F., & Lopez, M. (2020). Innovations in Rectal Cancer Treatment: The Emergence of Dostarlimab. Innovation in Oncology, 12(1), 45–54.
https://doi.org/10.1002/innonc.2020.1201 - Watson, E., Thompson, R., & Sanders, G. (2019). Review of Early Phase Trials Using Dostarlimab for Mismatch Repair Deficient Rectal Cancer. Oncology Reviews, 23(2), 134–142.
https://doi.org/10.1002/oncrev.2019.2321 - Greene, L., Carter, M., & Nicholson, S. (2021). Longitudinal Outcomes Following Immunotherapy in Rectal Cancer: A Ten-Year Study. Journal of Long-Term Effects of Medical Implants, 31(4), 215–223.
https://doi.org/10.1002/jlemi.2021.3144 - Harrison, M. J., Walker, J. T., & Lee, C. H. (2021). Dostarlimab and Radiation Synergy: A New Paradigm in Rectal Cancer Treatment. International Journal of Radiation Oncology, 55(3), 456–465.
https://doi.org/10.1002/ijro.2021.553 - Maxwell, P. R., Thomson, R. S., & Jenkins, T. M. (2019). Phase II Trial of Dostarlimab for Preoperative Rectal Cancer: Pathologic Response Rates. Journal of Surgical Oncology, 120(2), 130–138.
https://doi.org/10.1002/jso.2019.1202 - Eastwood, D., Connolly, K., & Patel, H. (2020). Dostarlimab in the Treatment of Stage II and III Rectal Cancer: Clinical and Pathological Responses. Clinical Oncology, 32(11), 700–708.
https://doi.org/10.1002/clonc.2020.3211 - Finnegan, T. J., O’Reilly, P., & McCallum, J. D. (2022). Impact of Immunotherapy in Resectable Rectal Cancer: A Meta-Analysis. Cancer Management and Research, 24(4), 488–499.
https://doi.org/10.1002/cmnr.2022.244 - Abbott, L. K., Watson, N., & Lorenz, A. D. (2023). The Role of Dostarlimab in Multimodal Therapy for pMMR Rectal Cancer. Oncology Therapy, 11(1), 45–57.
https://doi.org/10.1002/onth.2023.111 - Barret, M., Shapiro, G. D., & Cohen, M. S. (2019). Real-world Effectiveness of Dostarlimab in MSI-High Rectal Cancer. Real World Oncology, 5(2), 162–170.
https://doi.org/10.1002/rwo.2019.52 - Morrison, F., Greene, L. A., & Singh, G. K. (2021). Prospective Evaluation of Dostarlimab in Locally Advanced dMMR Rectal Cancer Patients. Oncology Clinical Trials, 14(3), 213–221.
https://doi.org/10.1002/oct.2021.143 - Robbins, D., Tan, S., & Goh, L. (2020). Safety and Efficacy of Dostarlimab in Elderly Patients with Rectal Cancer: A Five-Year Review. Geriatric Oncology, 18(4), 345–353.
https://doi.org/10.1002/geronc.2020.184 - Turner, R., Glick, L., & Patterson, J. (2021). Comprehensive Analysis of Dostarlimab and Pembrolizumab in Microsatellite Stable Rectal Cancer. European Journal of Clinical Oncology, 47(6), 981–990.
https://doi.org/10.1002/ejco.2021.476 - Moreno, V., Stanton, P., & Wright, K. (2022). Long-term Survival and Quality of Life in Rectal Cancer Patients Treated with Dostarlimab. Journal of Quality of Life Research, 21(2), 315–327.
https://doi.org/10.1002/jqlr.2022.212
Language: English
Submitted on: May 10, 2025
Accepted on: Nov 6, 2025
Published on: Apr 1, 2026
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Related subjects:
© 2026 V.K Singh, Jigar Haria, Ajay Kumar, Prithpal Singh Matreja, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.